Review



nc mimics r04602  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress nc mimics r04602
    Nc Mimics R04602, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/10__1007_slash_s10616___026___00970___4-71-55-62
    Average 94 stars, based on 27 article reviews
    nc mimics r04602 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Negative Control:

    Article Title: Analysis of Serum VCAN-AS1 Expression Level in Patients with Cerebral Infarction Secondary Epilepsy and Its Mechanism by Regulating miR-885-3p/NTNG1.
    Article Snippet: 1 Department of Neurology, Baotou Central Hospital, Baotou 014040, China 2 Guizhou Medical University, Guizhou 550004, China 3 Department of Rehabilitation, The Second Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei, China 4 Department of Pharmacy, The Second Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei, China 5 Medical Section, The Second Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei, China 6 Rehabilitation Nursing, The Second Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei, China 7 Department of Traditional Chinese Medicine, The Second Hospital of Qinhuangdao, Qinhuangdao 066000, Hebei, China 8 Department of Neurology, The Air Force Hospital of Southern Theater Command, PLA, No. 801 Dongfeng East Road, Yuexiu District, Guangzhou 510602, Guangdong, China Abstract VCAN-AS1 is a novel long non-coding RNA that participates in diverse disease processes, but the mechanism of its action in cerebral infarction secondary epilepsy (CISE) is unclear.. The potential action mechanism of VCAN-AS1 in CISE was explored by this study.. VCAN-AS1 and its downstream targets, namely miR-885-3p and Netrin G1 (NTNG1), were screened by the GEO, LncRNASNP2, and miRDB databases.



    Similar Products

    94
    MedChemExpress nc mimics r04602
    Nc Mimics R04602, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/10__1007_slash_s10616___026___00970___4-71-55-62
    Average 94 stars, based on 1 article reviews
    nc mimics r04602 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress microrna inhibitor negative control
    Microrna Inhibitor Negative Control, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/custom%40hy-ri04602%4041804264
    Average 94 stars, based on 1 article reviews
    microrna inhibitor negative control - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress inhibitor inhibitor negative control
    Inhibitor Inhibitor Negative Control, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/pm41779276-63-7-17
    Average 94 stars, based on 1 article reviews
    inhibitor inhibitor negative control - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Genechem inhibitor negative control lentivirus
    Inhibitor Negative Control Lentivirus, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/378a+3p+adenoviruses+mir/pm41670849-189-27-33
    Average 86 stars, based on 1 article reviews
    inhibitor negative control lentivirus - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    MedChemExpress negative control inhibitor
    Negative Control Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/pmc13137787-298-34-37
    Average 94 stars, based on 1 article reviews
    negative control inhibitor - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress mirna inhibitor negative control
    CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression <t>via</t> <t>miR‐145a‐5p</t> sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control <t>anti‐miRNA</t> and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.
    Mirna Inhibitor Negative Control, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/pmc12948252-454-17-25
    Average 94 stars, based on 1 article reviews
    mirna inhibitor negative control - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    86
    Bioneer Corporation negative control inhibitor
    CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression <t>via</t> <t>miR‐145a‐5p</t> sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control <t>anti‐miRNA</t> and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.
    Negative Control Inhibitor, supplied by Bioneer Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/control+negative/pmc12579414-64-15-19
    Average 86 stars, based on 1 article reviews
    negative control inhibitor - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    MedChemExpress inhibitor nc
    CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression <t>via</t> <t>miR‐145a‐5p</t> sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control <t>anti‐miRNA</t> and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.
    Inhibitor Nc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/inhibitor+inhibitor+negative+control/MicroRNA+Inhibitor+Negative+Control/pm41162983-99-16-19
    Average 94 stars, based on 1 article reviews
    inhibitor nc - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    Image Search Results


    CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression via miR‐145a‐5p sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.

    Journal: Advanced Science

    Article Title: Circular RNA PTPN4 Contributes to Blood‐Brain Barrier Disruption during Early Epileptogenesis

    doi: 10.1002/advs.202502250

    Figure Lengend Snippet: CircPTPN4 disrupts tight junction by upregulating ECE‐1 expression via miR‐145a‐5p sponging in BMECs. A) Quantitative RT‐PCR analyses of ECE‐1 mRNA levels in BMECs co‐cultured with Control neurons or Mg 2 ⁺‐free neurons, and transduced with either Control‐ShRNA or CircPTPN4‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p = 0.0004, ShRNA‐CircPTPN4‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs). B) Western blot analyses of ECE‐1 protein levels in the cortex of Control and SE‐24 h mice infected with Control‐ShRNA or CircPTPN4‐ShRNA lentivirus. C) Bar graph quantifying ECE‐1 protein levels as the intensity ratio of ECE‐1 to GAPDH ( n = 5; p < 0.0001, ShRNA‐Ctrl‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated Ctrl mice; p < 0.0001, ShRNA‐CircPTPN4‐treated SE‐24 h mice versus ShRNA‐Ctrl‐treated SE‐24 h mice). D) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs transduced with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0048, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p < 0.0001, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). E) Quantitative RT‐PCR analyses of ECE‐1 mRNA expression in Mg 2+ free N BMECs infected with OE‐Ctrl or OE‐CircPTPN4 lentivirus, and co‐treated with miR Control or miR‐145a‐5p mimics ( n = 5; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR‐145a‐5p mimics and OE‐Ctrl BMECs; p < 0.0001, miR Control and OE‐Ctrl BMECs versus miR Control and OE‐CircPTPN4 BMECs; p < 0.0001, miR Control and OE‐CircPTPN4 BMECs versus miR‐145a‐5p mimics and OE‐CircPTPN4 BMECs). F) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors. G) Bar graph showing quantification of Occludin staining intensity in Mg 2+ free N BMECs infected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐infected with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0066, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0049, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). H) Bar graph showing the permeability of Mg 2+ free N BMECs transfected with ShRNA‐Ctrl or ShRNA‐CircPTPN4 lentivirus, and co‐treated with anti‐miR Control or miR‐145a‐5p inhibitors ( n = 5; p = 0.0021, anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs versus Control anti‐miRNA and ShRNA‐Ctrl BMECs; p = 0.0045, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus Control anti‐miRNA and ShRNA‐CircPTPN4 BMECs; p = 0.0002, anti‐miR‐145a‐5p and ShRNA‐CircPTPN4 BMECs versus anti‐miR‐145a‐5p and ShRNA‐Ctrl BMECs). I) Representative immunofluorescence images of Occludin staining in Mg 2+ free N BMECs co‐cultured with Control or Mg 2 ⁺‐free neurons, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus. J) Bar graph showing quantification of Occludin staining in Ctrl N BMECs or Mg 2 ⁺‐free N BMECs, and infected with Control‐ShRNA or ECE‐1‐ShRNA lentivirus ( n = 5; p < 0.0001, ShRNA‐ECE‐1‐treated Ctrl N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p =0 .0108, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs; p = 0.0004, ShRNA‐Ctrl‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐Ctrl‐treated Ctrl N BMECs; p < 0.0001, ShRNA‐ECE‐1‐treated Mg 2 ⁺‐free N BMECs versus ShRNA‐ECE‐1‐treated Ctrl N BMECs). Values represent means ± S.E.M. Statistical analysis were performed using one‐way ANOVA followed by Tukey's test. Scale bar = 25 µm.

    Article Snippet: The miR‐145a‐5p mimics (HY‐ R00282 ), miRNA mimics negative Control (HY‐ R04602 ), miR‐145a‐5p inhibitor (HY‐RI00282), and miRNA inhibitor negative Control (HY‐RI04602) were purchased from Med Chem Express (MCE).

    Techniques: Expressing, Quantitative RT-PCR, Cell Culture, Control, Transduction, shRNA, Western Blot, Infection, Immunofluorescence, Staining, Permeability, Transfection